Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
AstraZeneca
Moodys
Merck
Harvard Business School

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Patent: 10,195,175

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,195,175
Title:Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
Abstract: The present invention relates to combination therapy with ADCs against a tumor-associated antigen, such as Trop-2, and drugs, such as microtubule inhibitors and/or PARP inhibitors. Where ADCs are used, they preferably incorporate SN-38 or another drug that induces DNA strand breaks. Preferably, the combination of ADC and PARPi or microtubule inhibitor exhibits synergistic effects against the cancer. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
Inventor(s): Goldenberg; David M. (Mendham, NJ), Cardillo; Thomas M. (Cedar Knolls, NJ)
Assignee: Immunomedics, Inc. (Morris Plains, NJ)
Application Number:15/481,090
Patent Claims:see list of patent claims

Details for Patent 10,195,175

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Emd Serono Inc BAVENCIO avelumab INJECTABLE;INTRAVENOUS 761078 001 2017-05-09   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2035-06-25 RX search
Astrazeneca Uk Ltd IMFINZI durvalumab INJECTABLE;INJECTION 761069 001 2017-05-01   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2035-06-25 RX search
Emd Serono Inc BAVENCIO avelumab INJECTABLE;INJECTION 761049 001 2017-04-25   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2035-06-25 RX Orphan search
Genentech Inc TECENTRIQ atezolizumab INJECTABLE; INJECTION 761041 001 2016-10-18   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2035-06-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
McKesson
Boehringer Ingelheim
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.